The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Review Article
The Continuation of Oral Medications with the Initiation of Insulin Therapy in Type 2 Diabetes: A Review of the Evidence
Abstract
The combination of oral medications with insulin is inevitable in the treatment of type 2 diabetes. Unfortunately, there are no consensus statements available to guide the continuation or discontinuation of specific therapies. The clinician treating the type 2 diabetic patient must be aware of the literature regarding use of oral medications in combination with insulin.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Nathan D, Buse J, Davidson B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithim for the initiation and adjustment of therapy. Diabetes Care 2008;31:1–11.
2. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1999;17:1100–1109.
3. Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–549.
4. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS-34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–865.
5. Holman R, Sanjoy P, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1–13.
6. Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389–396.
7. Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double blind, placebo-controlled trial. Ann Intern Med 1999;131:182–188.
8. Robinson A, Burke J, Robinson S, et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21:701–705.
9. Relimpio F, Pumar A, Losada F, et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial. Diabetes Med 1998;12:997–1002.
10. Fristche A, Schmullin RM, Haring HU, et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000;37:13–18.
11. Ponssen H, Elte J, Lehert P, et al. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 2000;22:709–718.
12. Strowig S, Aviles-Santa M, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691–1698.
13. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat to Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–3086.
14. Yki-Järvinen H, Tiikkainen M, Vahatalo M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442–451.
15. Douek IF, Allen SE, Ewings P, et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22:634–640.
16. Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab Res Rev 2008;24:3–13.
17. Metformin. Available at: www.drugstore.com. Accessed March 30, 2009.
18. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med 1998;128:165–175.
19. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998;280:1490–1496.
20. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531–539.
21. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182–188.
22. Wright A, Burden AC, Paisey RB, et al; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330–336.
23. Standl E, Maxeiner S, Raptis S, et al; HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28:419–420.
24. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254–259.
25. Holman R, Thorne K, Farmer A, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–1730.
26. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735–741.
27. Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952–959.
28. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007;9:96–102.
29. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.
30. Hermann LS, Scherstén B, Bitzén PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100–1109.
31. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389–394.
32. Glyburide. Available at: www.drugstore.com. Accessed March 30, 2009.
33. Maggs Dg, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double blind, placebo-controlled trial. Ann Intern Med 1998;128:176–185.
34. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341–367.
35. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217–224.
36. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605–1611.
37. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1:165–172.
38. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:71–72.
39. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2007;17:40–47.
40. Rosenstock J, Goldstein BJ, Vinik AI, et al; RESULT Study Group. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULfonylureaTitration (RESULT) Study. Diabetes Obes Metab 2006;8:49–57.
41. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395–1409.
42. Rosak C, Petzoldt R, Wolf R, et al. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract 2005;59:1131–1136.
43. Rosenstock J, Einhorn D, Hershon K, et al; Pioglitazone 014 Study. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251–257.
44. Mattoo V, Eckland D, Widel M, et al; H6E-MC-GLAT study group. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, multicenter, parallel group study. Clin Ther 2005;27:554–567.
45. Davidson JA, Perez A, Zhang J; Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006;8:164–174.
46. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improve vascular dysfunction by different mechanisms. Diabetes Care 2008;31:121–127.
47. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007;9:512–520.
48. Raskin P, Rendell M, Riddle MC, et al; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226–1232.
49. Yilmaz H, Gursoy A, Sahin M, et al. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol 2007;44:187–192.
50. Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004;27:841–856.
51. Actos (Pioglitazone) Full Prescribing Information. Takeda Pharmaceuticals America, Lincolnshire, IL; Eli Lilly and Company, Indianapolis, IN, 1999.
52. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256–263.
53. Pioglitazone and Rosiglitazone. Available at: www.drugstore.com. Accessed March 30, 2009.
54. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876–913.
55. Buse JB, Henry RR, Han J, et al; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628–2635.
56. Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–1100.
57. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–1091.
58. Aschner P, Kipnes MS, Lunceford JK, et al; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–2637.
59. Nauck MA, Meininger G, Sheng D, et al; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205.
60. Scott R, Loeys T, Davies MJ, et al; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959–969.
61. Byetta [Package Insert.] San Diego, CA, Amylin Pharmaceuticals, Inc., 2007.
62. Januvia [Package Insert.] Whitehouse Station, NJ, Merck & Co., Inc., 2006.
63. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285–292.
64. Bhatia R, Viswanathan P, Chaudhuri A, et al. Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1c in obese type 2 diabetics on insulin. Presented at Program and Abstracts of the American Diabetes Association 66th Scientific Sessions. June 9–13, 2006, Washington, DC, Abstract 422-P.
65. Exenatide. Available at: www.drugstore.com. Accessed March 30, 2009.
66. Fonseca V, Schweizer D, Albrecht M, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148–1155.
67. Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40:427–430.
68. Sitagliptin. Available at: www.drugstore.com. Accessed March 30, 2009.
69. Acarbose [Package Insert.] Bonita Springs, FL, Cobalt Laboratories, Inc., 2006.
70. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;2:CD003639.
71. Hara T, Nakamura J, Koh N, et al. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996;19:642–647.
72. Schnell O, Mertes G, Standl E; Acarbose-Insulin Combination Study Group. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007;9:853–858.
73. Standl E, Baumgarti H, Fuchtenbusch M, et al. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late sulfonylurea failure. Diabetes Obes Metab 2001;4:215–220.
74. Guvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999;36:93–97.
75. Hamiyet Y, Gursoy A, Sahin M, et al. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol 2007;44:187–192.
76. Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind, placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995;18:928–932.
77. Kelley DE, Bidot P, Freedman Z, et al. Efficacy and safety of acarbose in insulin- treated patients with type 2 diabetes. Diabetes Care 1998;21:2056–2061.
78. Acarbose. Available at: www.drugstore.com. Accessed March 30, 2009.
